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Objective: Acute rejection (AR) after lung transplantation (LTx) requires prompt intervention.
Most episodes respond to steroid pulse therapy. The aim of this study was to evaluate clinical
indicators for non-response to steroid treatment in biopsy proven AR after the early postoper-
ative period.
Methods: We prospectively analysed 85 patients more than 6 months after LTx with symptom-
atic biopsy proven AR (grade A1) from Jan. 2005 until Nov. 2007 in a single centre. In 47
patients, AR was steroid-sensitive (group 1), 38 patients did not respond to steroid pulse
therapy (group 2). All AR episodes were associated with clinical symptoms. Fifty-seven (67%)
were low-grade rejections (ISHLT A1).
Results: Independent clinical predictors for steroid response vs. non-steroid response in biopsy
proven AR were ‘‘days after transplantation’’ (pZ 0.01, adjusted hazard ratio (HR) 1.2),
‘‘decline in home spirometry slope’’ (pZ 0.03, HR 0.97), ‘‘adherence to home spirometry’’
(pZ 0.05, HR 0.98) and ‘‘serum CRP’’ (pZ 0.02, HR 0.87). Eight patients (21%) of group
2 developed BOS during the following 6 months.
Conclusions: Early detection of deterioration in graft function seems to be crucial for effective
treatment of AR. Home spirometry seems to be useful in detecting early changes in graft func-
tion and surveillance protocols could be potentially helpful in predicting patients likely to
demonstrate a steroid response.
ª 2009 Elsevier Ltd. All rights reserved.115328505.
h-hannover.de (T. Fuehner).
9 Elsevier Ltd. All rights reservedIntroduction
Lung transplantation has become an accepted intervention
for patients with advanced lung disease.1 Long-term
survival for lung recipients is limited mainly by.
Table 1 Inclusion and exclusion criteria.
Inclusion criteria
Double lung- or heart-lung transplantation more than
6 months before inclusion
Biopsy proven AR ( grade A1, according to ISHLT
criteria6) with clinical symptoms (new onset of dyspnoea,
hypoxemia. cough, low-grade fever, infiltrates,
effusion etc)
Decline in FEV1 10% comparing to previous outpatient
visit
At previous outpatient clinic visit stable functional
situation (FEV1 90% of best-FEV1)
No steroid pulse therapy during the last 4 months
minimum of 6 months of follow-up
Exclusion criteria
Change in immunosuppressive regimen within last
6 months
Acute infection (see definition in method part)
BOS (stage 0p-3, according to ISHLT criteria6)
AX grade in histopathology
Other complications (e.g. stenosis, defined by
bronchoscopic intervention explaining deteriorating graft
function)
Table 2 Baseline characteristics.
Variable Patients (total)
Days after TX (d) Median 652 (181e4576)
Patients (n) 85
Age (y) Median 42 (20e66)
Gender, female n (%) Female 36 (42)
Underlying disease Emphysema 37 (43%)
Idiopathic fibrosis 13 (15%)
Cystic fibrosis 27 (32)
Others 8 (10%)
Type of transplant, n DLT 81, HLT 4
Immunosuppressive regimen
at time of rejection
Cyclosporin 57 (66%)
Tacrolimus 29 (34%)
Prednisolon 85 (100%)
MMF 71 (84%)
Everolimus 14 (16%)
FEV1 baseline (ml/s) Mean 2516 735 (88% from
best-FEV1), range
1215e4240
Days between last follow up
and date of rejection (d)
Median 53 (14e210)
Indicators for steroid response in biopsy 1115opportunistic infections and chronic rejection. Acute
cellular rejection has been identified as the primary risk
factor for chronic organ dysfunction/bronchiolitis obliter-
ans syndrome (BOS).2e5 It has been graded according to
histopathological changes.6e8 Studies examining the impact
of acute rejection on BOS have established a strong asso-
ciation between high-grade acute rejection (A2), recur-
rent episodes of acute rejection, a cumulative burden of
acute rejection and episodes of late acute rejection with
BOS.9e11 Even a single episode of minimal acute rejection
(grade A1) without recurrence or subsequent progression to
a higher grade is a risk factor significant for BOS and
requires therapy.12,13 Symptomatic and high-grade AR
(A2) should be promptly treated with intravenous steroid
pulse therapy along with adoption of the immunosup-
pressive regimen. Steroid-resistant AR may be treated by
anti-lymphocyte globulins or may reflect an alternative
underlying process.
Transbronchial lung biopsy is currently the most sensi-
tive and specific test for lung rejection and allows the
differentiation from infection. However, it is an invasive
procedure requiring bronchoscopy, which is not always
tolerated well by patients and carries obvious limitations
as a tool for repeat testing.14 Previous studies using
a combined approach with bronchoalveolar lavage fluid
(BALF, to exclude infection) and transbronchial lung biopsy
(TBB) have reported that the sensitivity for the detection of
AR ranges from 60% to 75% in recipients of heartelung (HLT)
and bilateral-lung (BLT) transplantation15,16 and from 48%
to 72% in recipients of single-lung transplantation.17 Daily
home spirometry with a portable spirometer is advocated in
the follow-up of lung transplant recipients by some centres
and may detect changes in graft function related to
rejection earlier.18e21
The aim of this study was to investigate the value of
different markers, e.g. lung function, home spirometry,
bronchoalveolar lavage fluid (BALF) and blood samples
(white blood cells (WBC), C-reactive protein, arterial blood
gases) on steroid sensitivity in acute graft rejection.
Methods
Study design
A prospective cohort study was performed in lung
and heartelung transplant recipients who were followed
in the outpatient clinic of Hannover Medical School from
Jan. 2005 until Nov. 2007. We analysed 85 patients
with symptomatic biopsy proven acute rejection (AR)
prospectively.
Patients were qualified for the study if they were at
least 6-month post-transplant, had biopsy proven AR,
decline in lung function (10% in FEV1 comparing to FEV1
during previous visit) with clinical symptoms. Patients were
at previous outpatient clinic visit in stable functional situ-
ation (FEV1 90% of best-FEV1). Surveillance biopsies were
not standard of our program during the study period.
Patients with pulmonary infections, established BOS and
other reasons for decline in graft function were excluded.
In-/exclusion criteria and baseline characteristics are
shown in Tables 1 and 2.Primary endpoint of this study was steroid response in
acute allograft rejection; secondary endpoint included
restitution in biopsy A grade and onset BOS.
Steroid response was defined as increase in FEV1 of at
least 10% after steroid pulse therapy compared to FEV1 at
rejection date (date of study inclusion). The therapeutic
success of steroid pulse therapy was evaluated at least 14
days after steroid pulse therapy. Patients were divided into
group 1: steroid-sensitive AR, and group 2: steroid-resistant
AR. Control biopsy for histopathological response was not
standard of our program. In steroid non-responders
1116 T. Fuehner et al.cytolytic therapy and/or change in immunosuppressive
regimen was routinely applied.
Prior to enrollment, the project had been approved by
the Institutional Review Board. All subjects gave written
informed consent before their participation in the program
and the study was approved by the local ethics committee.
The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) Statement was used as a guideline
for reporting the study results.22
Standard of care
Standard maintenance immunosuppression consisted of
a triple drug regimen, including a calcineurin inhibitor, pred-
nisolone, and a mycophenolate mofetil or an mTOR
(mammalian target of rapamycin)-inhibitor. Patients with
recurrent or steroid-resistant episodes of rejection were
switched fromcyclosporine to tacrolimus.Tacrolimuswasused
as the primary calcineurin inhibitor in patients after HLTx. In
target trough level was defined as desired trough level 10%.
AR was treated with adoption of immunosuppressive
therapy where necessary, using intravenous methylpred-
nisolone 15 mg/kg/day for 3 days. Based on histological
severity of findings, presence of associated symptoms and
prior biopsy grades, the maintenance immunosuppressive
regimen was suitably modified.
Bronchoscopy
Bronchoscopy was performed in patients with new respi-
ratory symptoms (i.e. dyspnoea, cough), signs (i.e. fever,
crackles), infiltrates on chest X-ray, and/or declining lung
function (i.e. decrease of FEV1 of 10% compared to
previous outpatient clinical visit).
Transbronchial lung biopsies were obtained from the
lung periphery with 2 or 2.5 mm fenestrated forceps (FB-
231D, Olympus, Hamburg, Germany) without routine fluo-
roscopic guidance. Five biopsies from one lung, two lobes
(sparing middle-lobe and lingula) and at least three
segments were targeted. Following all biopsies, a chest
X-ray was performed after 1e2 h to exclude any possible
pneumothoraces.
The severity of acute rejection was graded according to
the criteria of the International Society for Heart and Lung
Transplantation (ISHLT).6e8 Specimens with less than 50
alveoli were graded as AX and did not comply with the
inclusion criteria.
Definitions of infection
Bacterial infection was given when any pulmonary path-
ogen was cultured with a bacterial load of more than
104 cfu/ml. Infection with community acquired respiratory
viruses (CARV) were defined as any positive results in direct
virus isolation (cultures), antigen testing or viral culture
for, Influenzavirus A and B, Parainfluenzavirus I-III, RSV and
Adenovirus. Fungal infection was defined as ‘‘proven’’ or
‘‘probable according to the EORTC/MSG consensus group
criteria.23 CMV infection was defined as direct CMV virus
isolation or detection of viral proteins or nucleic acid in any
body fluid or tissue specimen.24 CMV antigen was routinelymeasured in LTx recipients. Significant antigenemia was
defined as more than 3/400,000 positive CMV-pp65 leuco-
cytes with initiation of antiviral therapy or adaptation of
immunosuppressive regimen.
Pulmonary function tests
Spirometry was performed according to ATS/ERS guide-
lines.25 BOS staging was defined as a FEV1< 80% best after
transplantation according to the International Society of
Heart and Lung Transplantation (ISHLT) system.26 Best-FEV1
was defined as the average of the two highest measure-
ments obtained at least 3 weeks apart during the post-
operative course. Home spirometry was recommended to
all recipients to be performed once daily (three expiratory
flow-volume parameters) and stored in a recording device
(AM1, Viasys Healthcare, Hochberg, Germany). Home
spirometry adherence was defined as measurements in
percentage of recommended measurements (max. 100%).
The subjects were instructed to contact their transplant
coordinator if they observed declining FEV1, or developed
new signs or symptoms. Patients were instructed to contact
their transplant centre immediately if a >10% decline in
home spirometry occurred.
Statistics
Data are reported as means (standard deviation), time
dependent variables are expressed as median (minimum
and maximum). All reported p-values are two-sided, unless
otherwise indicated. For all analyses, p-values <0.05 were
considered statistically significant.
For univariate analysis, categorical variables were
analyzed by chi-squared test or Fisher’s exact test. Medians
were compared with the ManneWhitney test. Means were
analyzed with Student’s t-test. Multivariate analysis
included logistic regression (for steroid response). All vari-
ables with a p-value <0.10 were included and variables with
a p-value of >0.10 were excluded in a multivariate analysis.
Receiver operating curves (ROC) were constructed to show
the correlation between predictors and steroid response. We
constructed a scoring system for steroid response quantifica-
tion (SRQ), using the clinically important variables or those
independently related to steroid response. The correlation
between SRQ and steroid response was evaluated with linear
regression analysis. For all analyses, a p-value <0.05 was
considered statistically significant. Statistical analysis was
conducted using SPSS 15.0 (SPSS Inc., Chicago, IL).
Results
This study included 85 double lung-/heartelung trans-
planted patients. The distribution of histopathological
findings of TBB and immunosuppressive regimens are shown
in Tables 2 and 3. Forty-seven patients had steroid-sensitive
AR (group 1) with recovery of lung function, while 38
patients did not respond to steroid pulse therapy (group 2)
despite biopsy proven AR. Eight patients (21%) of group 2
developed BOS during the following 6 months (Fig. 1).
Immunosuppressant levels were analyzed retrospec-
tively over 3 months before the date of biopsy proven
Table 3 Histological grading of lung biopsies.
Vascular rejection Group 1 (nZ 47) Group 2 (nZ 38) Airway rejection Group 1 (nZ 47) Group 2 (nZ 38)
A0 0 0 B0 5 3
A1 29 28 B1 20 13
A2 18 10 B2 12 12
A3 0 0 B3 0 0
A4 0 0 B4 0 0
AX 0 0 BX 10 10
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measured in group 1 and 152 levels in group 2 (1.3 measured
levels/month/patient in group 1, 1.4 measured levels/
month/patient in group 2). Immunosuppressant in target
levels and history of rejection episodes was not significantly
different between both groups (pZ 0.84, pZ 0.57). The
immunosuppressive regimen was switched in 7/47 patients
of group 1 (15%) once before, in 1/47 patient twice before
the study period (2%). The immunosuppressive regimen
during the postoperative period was changed in group 2 in
8/38 (22%) pts. once and in 1/38 (3%) patient three times
(of total: 38) (Table 4).
We abstained from control biopsies in case of complete
recovery of graft function (FEV1 100% compared to previous
FEV1 in outpatient clinic) in the absence of new clinical find-
ings. In case of incomplete recovery of graft function, control
biopsies were performed in 22/47 (49%) patients of group 1
and 21/38 (55%) patients in group 2 after median 42 days (14e
90). In group 1, two patients with A2 rejection stepped down
to A1, in group 2 in 1 patient with A2 rejection changed to A1
rejection. All otherbiopsies turned toA0 (70%). Fromthe eight
patients developing BOS 6 months later, half of them received
control biopsies within 3 month after rejection date. All of
them turned from A1 to A0.
Univariate analysis showed ‘‘days after transplantation’’
(pZ 0.01), ‘‘days between last follow up and rejection
date’’ (pZ 0.01), ‘‘decline in FEV1 slope’’ (pZ 0.01),
‘‘decline in home spirometry slope’’ (pZ 0.02) and ‘‘adher-
ence home spirometry’’ (0.01) as significant (Table 4).85 p
Symptomatic AR (n = 85)
steroid sensitive: 47 pts.
(= increase in FEV1 ≥ 10%)
Not ste
(= no
30 pts. with incomplete recovery
without BOS definition
(after 6 months)
Figure 1 FlThere was no significant difference between age, gender,
underlying disease, type of transplantation, immunosup-
pressive regimen at time of rejection nor FEV1 baseline
(ml/s). Serum marker CRP (pZ 0.01) and BALF eosinophils
(pZ 0.01) proved to be significant. Blood gas analysis and
histological grading of rejection could not been identified
as significant different (Table 4).
Multivariate analysis revealed that ‘‘days after trans-
plantation’’ (pZ 0.01, adjusted hazard ratio (HR) 1.2),
‘‘decline in home spirometry slope’’ (pZ 0.03, HR 0.97),
‘‘adherence home spirometry’’ (pZ 0.05, HR 0.98) and
‘‘serum CRP’’ (pZ 0.02, HR 0.87) were independent risk
factors. ‘‘Decline in FEV1 slope’’ and ‘‘home spirometry
decline before contact’’ did not reach statistical signifi-
cance as independent risk factors. Overall, ‘‘days after
transplantation’’ showed the highest significance
(pZ 0.01) (Table 5).
Receiver operating curves (ROC) demonstrated the high
prognostic value of ‘‘days after transplantation (d)’’ to
predict steroid-sensitivity in acute graft rejection (Fig. 2).
Eighty-five percent of patients showed response to steroid
pulse therapy in case of proven acute rejection during the
first year after transplantation, if only 55% of patients did
respond to steroids 2 years after transplantation. Fig. 3
demonstrates that SRQ related significantly to steroid
response (p< 0.01), with total scores between 0 and 8,
respectively, demonstrating 20%, 0%, 8%, 29%, 50%, 82%,
86%, and 100% likelihood of a steroid response (Table 6,
Fig. 3).ts. with AR (≥ A1)
Asymptomatic AR
(exclusion criteria)
roid sensitive: 38 pts.
 increase in FEV1)
3 pts. (8%) with BOS grade 0p
(after 6 months)
5 pts. (13%) with BOS grade 1
(after 6 months)
ow chart.
Table 4 Univariate analysis.
Variable Group 1 Group 2 p-value
Days after Tx (d) 296 (183e1531) 1008 (181e4576) 0.01
Days between last follow up and rejection date (d) 44 (8e145) 61 (22e178) 0.01
Immunosuppressive regimen changes before 8a 9a 0.16
In target immunosuppressant levels (%)b 80% (10% decreased) 74% (9% decreased) 0.84
Previous rejection episodes (A1) 0.7 0.7 0.8 0.9 0.57
Decline in FEV1 slope (ml/d) 19 19 7 7 0.01
Home spirometry decline before contact (d) 10 10 31 19 0.01
Decline in home spirometry slope (ml/d) 58 39 23 21 0.02
Adherence home spirometry (%) 86 25 62 31 0.01
BALF kymphocytes/ml 5 8 9 11 0.27
BALF eosinophils/ml 0 1 1 3 0.01
BALF neutrophils/ml 25 28 23 28 0.86
CRP serum level (mg/l) 12 13 5 4 0.01
WBC (103/ml) 7 3 7 2 0.64
pO2 (mmHg) 80 10 77 10 0.47
a In one patient of each group immunosuppressive regiment was changed twice (group 1)/three times (group 2).
b Included all immunosuppressant levels measured in each patient from three month before to date.
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Our data demonstrate a different clinical profile for
patients with steroid sensitivity outside the first 6 post-
operative months after LTx to those which exhibited no
response to steroid therapy. Primarily we could show that
time after Tx, more rapid decline and adherence to home
spirometry and serum CRP are independent predictors for
steroid sensitivity.
Several earlier studies have shown the diagnostic value
of home spirometry for graft dysfunction.15,18 In places
where patients live at long-distances from their transplant
centre diagnostic tools like home spirometry might be
particularly helpful. Predictably, adherence to home
spirometry appears to vary between individuals and may be
monitored by home spirometry because it is a risk factor for
negative clinical outcomes in relation to acute rejections,
graft vasculopathy, higher costs, and mortality.27 We could
demonstrate that both adherence to home spirometry
along with the pattern of decline (fast decline in home
spirometry slope ml/d) are independent prognostic markers
for steroid sensitivity in allograft rejection, and therefore
could additionally influence the long-term outcome.
Home spirometry decline before contact as another marker
for adherence was shown (d) (pZ 0.01).Table 5 Multiple logistic regression analysis with steroid-sensit
Variable Adjusted hazard
ratio (HR)
Correl
Days after
transplantation (d)
1.2 0.2
Decline home
spirometry slope (ml/d)
0.97 0.2
Adherence home
spirometry (%)
0.98 0.14
CRP (mg/l) 0.87 0.65With serum marker CRP we could find another straight-
forward tool associated with low costs to be a significant
marker of steroid sensitivity. Other markers like serum
procalcitonin (PCT) need to be evaluated. Differences in
BALF cell counts did not seem to be significant for risk
stratification, although our data showed in univariate
analysis BALF eosinophiles as significantly different
(pZ 0.01). Nevertheless our analysis could not show that
BALF eosinophiles are independent predictor for steroid
response in multivariate analysis. Although increased
eosinophils in BALF have been observed in allograft rejec-
tion, this relationship is less well defined. The role of
eosinophils in the pathophysiology of allograft rejection is
unclear.28
Of particular concern is that only 55% of all patients had
steroid-sensitive disease. There is still debate about the
specificity of transbronchial biopsies in diagnosing acute
rejection. Also, surveillance biopsies are not uniformly
applied in the follow-up care of lung transplant recipients
worldwide especially not after the early postoperative
period. Complications may pose a greater risk than indi-
cation led to bronchoscopy. In this study, performing
transbronchial indication biopsies in outpatient lung-
transplant recipients proved to be safe. In addition, inter-ivity as dependent variable.
ation coefficient (r) 95% CI of Exp (B) p-value
1.03e1.4 0.01
0.85e0.97 0.03
0.94e0.98 0.05
0.78e0.98 0.02
Figure 2 Ability of (a) days after transplantation, (b) home spirometry slope (ml/d), (c) adherence to home spirometry (%) and
(d) CRP (mg/ml) to predict non-steroid sensitivity in ROC-curves.
Figure 3 (a) Association between steroid response quantifi-
cation score (SRQ) and steroid response (%) (p< 0.01). (b)
Significance, specificity, negative predictive value (NPV) and
positive predictive value (PPV) score for 5e8 points.
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TBB interpretation could be shown to vary.29e31
Our data could show that patients of group 1 tend to be
earlier in their postoperative course than patients in group
2 (296 vs. 1008 days post Tx, Table 4). The information that
only 55% responded to steroid pulse therapy after the
second postoperative year should be considered in future
therapy regimens. Our results question the clinical impor-
tance of acute cellular rejection in pts. ‘‘late’’ after LTx. In
lung transplant recipients more than 2 years after surgery
with declining graft function and refractory to steroid pulse
therapy, a further intensive work-up for BOS (CT scan,
exclusion of gastroesophageal reflux, etc.) is warranted.
Risks of transbronchial biopsy (bleeding, pneumothorax)
should be weighed against the benefit of additional findings
of biopsy (e.g. infection or malignancy).
Several studies have demonstrated that acute rejection
can be present in asymptomatic lung transplant recipients
in around 25% of patients monitored by surveillance biop-
sies, which might be a confounding mechanism influencing
BOS.32,33 Histopathological findings in BOS patients is
a poorly studied area. Martinu et al. reviewed in 12
patients’ pathological findings in explanted allografts which
underwent pulmonary re-transplantation for BOS. They
Table 6 Scoring system for steroid response quantifica-
tion (SRQ).
Score points 0 1 2
Days after
transplantation (d)
>360 183e360 <183
Decline in home
spirometry slope (ml/d)
<10 10e30 >30
Adherence home
spirometry (%)
<50 50e80 >80
CRP (mg/l) <5 5e10 >10
1120 T. Fuehner et al.described findings of acute cellular rejection with marked
heterogeneity (A1e3) in 100% explanted lungs. This might
contribute to the variability of patient responses to treat-
ment.34 In our study 21% in group 2 developed BOS during
the following 6 months. Our findings of mild A-grade
rejection also in patients with early BOS in next half year
complement with Martinu et al. and underlines the vari-
ability of clinical findings in patients with OB/BOS after lung
transplantation. That biopsy proven acute rejection
occurring more than 2 years after transplantation is more
likely to be steroid-resistant represents new information.
To our knowledge, there is no prospective study which
demonstrated this effect. Early recognition of deteriorating
graft function by home spirometry may give clinicians
a window of opportunity for earlier diagnosis and therapy in
pts. with AR or onset of BOS.
We obtained 3.2 biopsy specimens in average per patient
at outpatient bronchoscopy, lower than the recommended
5 specimens according to the current guidelines.6 Signs of
respiratory failure and significant bleeding (suction of
>100 ml blood) limited in some cases to obtain the required
number in the majority of patients with less than five
biopsy specimen. Discussion continues regarding the
implicit loss of diagnostic sensitivity in TBB series that
report too few biopsies per procedure when attempting to
compare contemporary studies.35
Nevertheless, the incomplete number of biopsies in
patients and the incomplete performance of control biop-
sies in group 2 after steroid pulse therapy are study limi-
tation. Another study limitation is that we ruled out
patients with any virus isolation but we did not detect for
HHV6,7 or human metapneumovirus in this study, which can
also be reasonable for graft dysfunction.36
In conclusion this study shows that an acute rejection
episode had a higher likelihood of responding to pulse
steroid therapy in lung transplanted patients ‘‘earlier’’
after surgery with a sudden decrease in lung function over
a short period, which demonstrated high adherence to
home spirometry and exhibited an associated elevated
serum CRP. Additionally, histopathological findings of mild
A grades are losing their expressiveness with the time after
transplantation. In case of incomplete clinical response to
steroid pulse therapy patients should be intensively moni-
tored for signs of BOS.
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